Pennsylvania HB305 mandates a cap on insulin copayments for health insurance policies, while also requiring an investigation into insulin pricing.

Pennsylvania HB305 amends the Insurance Company Law of 1921 to limit copayments, coinsurance, or deductibles for insulin to no more than $35 per thirty-day supply. This provision applies to health insurance policies offering prescription coverage for insulin, excluding certain types of policies. The bill also tasks the Attorney General with investigating insulin pricing practices, including business practices and data from manufacturers, and to submit a report to the General Assembly within a year.

Pennsylvania HB305 mandates a cap on insulin copayments for health insurance policies, while also requiring an investigation into insulin pricing.

Pennsylvania HB305 amends the Insurance Company Law of 1921 to limit copayments, coinsurance, or deductibles for insulin to no more than $35 per thirty-day supply. This provision applies to health insurance policies offering prescription coverage for insulin, excluding certain types of policies. The bill also tasks the Attorney General with investigating insulin pricing practices, including business practices and data from manufacturers, and to submit a report to the General Assembly within a year.